Tumor cells can express the PD-L1 protein to protect themselves from immune system attack by binding to the PD-1 receptor on T cells, which suppresses the T cells’ ability to destroy the tumor.15 PD-L1 is frequently over expressed in placenta, and many human tumors such as melanoma, diffuse large B-cell lymphoma, and carcinomas of the […]
HPV Probes Download HPV 6 Probe Download HPV 11 Probe Download HPV 16 Probe Download HPV 18 Probe Download HPV 31 Probe Download HPV 51 Probe Download CISH DNA 1 Temp1 Download CISH DNA 2 Temp1 Download ONCORE Pro Warp Red Chromogen Kit Download ONCORE Pro Hematoxylin Download Molecular Probe / Templates Download ALK […]
![Tonsil stained with TIGIT [BC41] antibody](https://biocare.net/wp-content/uploads/3254.jpg)
T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory domain (TIGIT) is a transmembrane glycoprotein receptor expressed in regulatory and memory T cells, natural killer (NK), and activated T cells (1). As a member of the immunoglobulin superfamily, TIGIT has coinhibitory effects on T-cell dependent immune responses, playing an important role in transplantation tolerance and tumor immune surveillance […]
August, 4 2020 – Biocare Medical LLC, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, in collaboration with Bethyl Laboratories announces the release of a new rabbit monoclonal antibody, TIGIT [BLR047F] antibody for in vitro diagnostic (IVD) use in the qualitative identification of the TIGIT protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded […]
T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory domain (TIGIT) is a transmembrane glycoprotein receptor expressed in regulatory and memory T cells, natural killer (NK), and activated T cells (1). As a member of the immunoglobulin superfamily, TIGIT has coinhibitory effects on T-cell dependent immune responses, playing an important role in transplantation tolerance and tumor immune surveillance […]
February 13, 2020 – Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, announces the launch of seven novel IVD IHC antibody markers for clinical diagnostics and research applications.The most recent launch focuses on several immuno-oncology markers, critical in aiding early-stage cancer drug developments and patient treatment. Biocare re-developed a major […]
Programmed death 1 (PD-1) is a cell surface co-receptor member of the CD28/CTLA-4 family, and functions as a downregulator of the immune system through a dual mechanism of inhibition (1). PD-1 is expressed on the cell surface of activated T- and B-cells. Anti-tumor immunity may be controlled by the PD-1/PD-L1 signaling pathway. PD-L1, one of […]
![Colorectal carcinoma stained with MSH6 [BC19]](https://biocare.net/wp-content/uploads/3215_MSH6-BC19.jpg)
MSH6 functions, along with MSH2, MLH1, and PMS2, as part of the DNA mismatch repair (MMR) pathway, are utilized by normal proliferating cells to repair mutations that may occur during DNA replication.16 MSH6 is a heterodimer of MSH2 and binds to DNA containing G/T mismatches. The MSH2-MSH6 complex recognizes a single-based mispair insertion/deletion loop.15,16 Antibodies […]
![Colorectal carcinoma stained with MLH-1 [BC23]](https://biocare.net/wp-content/uploads/3214_MLH-1-BC23.jpg)
The BC23 antibody recognizes human and mouse MLH1 (80-85 kDa). The repair of mismatch DNA is essential to maintaining the integrity of genetic information over time. An alteration of microsatellite repeats is the result of slippage owing to strand misalignment during DNA replication and is referred to as microsatellite instability (MSI) (1-3). These defects in […]
Immunohistochemical staining for programmed cell-death ligand 1 (PD-L1) in malignant thymoma and thymic carcinoma. Alexei Shimanovsky, Richard Cartun, Mary Fiel-Gan, Daniza Mandich, Jonathan Earle, Andrew L. Salner… Abstract e20003 Background: Recent development of anti-PD-1/L1 antibodies has demonstrated activity in various neoplasms. Thymic malignancies (TMS) are rare and treatment in advanced disease is limited. To evaluate […]
